A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.
Status:
Recruiting
Trial end date:
2022-06-13
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once
daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having
achieved normokalemia following 24 or 48 hours of initial ZS therapy (10g TID).